Table 6.

Risk of Myocardial Scar at Year 10 in Relation to Baseline NT‐proBNP Quartiles, by Myocardial Scar Groups

Models*	NT‐proBNP Quartiles (pg/mL)				P Trend †
	Q1 (5 to <24) Reference	Q2 (24 to <55)	Q3 (55 to <112)	Q4 (≥112)
	Odds Ratio (95% CI) ‡
Ischemic scar
No. of cases/total (51/1498)	13/492	8/406	14/358	16/242
Unadjusted	1.0	0.7 (0.3–1.8)	1.5 (0.7–3.2)	2.6 (1.2–5.5)‖	0.006
Model 1	1.0	0.7 (0.3–1.8)	1.6 (0.7–3.6)	2.8 (1.2–6.9) §	0.013
Model 2	1.0	0.7 (0.3–1.7)	1.3 (0.6–3.2)	2.5 (1.1–6.8) §	0.040
Nonischemic scar
No. of cases/total (62/1498)	17/492	22/406	10/358	13/242
Unadjusted	1.0	1.6 (0.8–3.1)	0.8 (0.4–1.8)	1.6 (0.8–3.3)	0.494
Model 1	1.0	1.8 (0.9–3.6)	1.1 (0.5–2.5)	2.3 (1.0–5.5) §	0.103
Model 2	1.0	1.8 (0.9–3.7)	1.0 (0.4–2.4)	2.3 (0.9–5.9)	0.148

NT‐proBNP indicates N‐terminal pro‐B‐type natriuretic peptide.

^*Model 1: adjusted for age, sex, and race (White [reference], African‐American, Chinese, Hispanic); Model 2: adjusted for all variables in model 1 plus education more than high school, physical activity (sex‐specific tertiles: low, middle, high), current cigarette smoking, diabetes mellitus, body mass index, systolic blood pressure, antihypertensive medication use, high‐density lipopeotein cholesterol, total cholesterol, statin medication use, and prevalence of coronary artery calcium score >10.

^† P for linear trend tested by entering log (NT‐proBNP) as a continuous variable in the same model.

^‡Odds ratio represents the odds of having scar at year 10 in the NT‐proBNP quartile relative to the reference category, adjusting for all other covariates in the model.

^§ P<0.05, ^‖ P<0.01.